DK1054887T3 - Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister - Google Patents

Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister

Info

Publication number
DK1054887T3
DK1054887T3 DK99906756T DK99906756T DK1054887T3 DK 1054887 T3 DK1054887 T3 DK 1054887T3 DK 99906756 T DK99906756 T DK 99906756T DK 99906756 T DK99906756 T DK 99906756T DK 1054887 T3 DK1054887 T3 DK 1054887T3
Authority
DK
Denmark
Prior art keywords
neuropeptide
receptor antagonists
pyrimidine derivatives
bicyclic pyridine
bicyclic
Prior art date
Application number
DK99906756T
Other languages
English (en)
Inventor
Mark H Norman
Nianhe Han
Christopher H Fotsch
Ning Chen
Longbin Liu
Clarence R Hurt
Tracy J Jenkins
Ofir A Moreno
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1054887T3 publication Critical patent/DK1054887T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
DK99906756T 1998-02-06 1999-02-05 Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister DK1054887T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7392798P 1998-02-06 1998-02-06
US7398198P 1998-02-06 1998-02-06
US9357798P 1998-07-20 1998-07-20
US9348298P 1998-07-20 1998-07-20
US09/246,775 US6187777B1 (en) 1998-02-06 1999-02-04 Compounds and methods which modulate feeding behavior and related diseases

Publications (1)

Publication Number Publication Date
DK1054887T3 true DK1054887T3 (da) 2006-05-08

Family

ID=27535987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99906756T DK1054887T3 (da) 1998-02-06 1999-02-05 Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister

Country Status (13)

Country Link
US (2) US6187777B1 (da)
EP (1) EP1054887B1 (da)
JP (1) JP2003502272A (da)
AT (1) ATE323088T1 (da)
AU (1) AU747920B2 (da)
CA (1) CA2319275C (da)
CY (1) CY1105476T1 (da)
DE (1) DE69930835T2 (da)
DK (1) DK1054887T3 (da)
ES (1) ES2257851T3 (da)
PT (1) PT1054887E (da)
SI (1) SI1054887T1 (da)
WO (1) WO1999040091A1 (da)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456836T1 (de) * 1996-09-04 2010-02-15 Intertrust Tech Corp Zuverlässige infrastrukturhilfssysteme, verfahren und techniken für sicheren elektronischen handel, elektronische transaktionen, handelsablaufsteuerung und automatisierung, verteilte verarbeitung und rechteverwaltung
JP4798814B2 (ja) * 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
EP1129089B1 (en) 1998-11-10 2005-12-28 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
DK1129091T3 (da) 1998-11-12 2002-11-04 Neurocrine Biosciences Inc Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
PT1165564E (pt) * 1999-04-08 2009-04-16 Einstein Coll Med Processo para a preparação de inibidores do metabolismo de nucleósidos
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
YU23602A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
AU7738000A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
JP2003533530A (ja) 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニスト
US7276492B2 (en) * 2000-06-01 2007-10-02 Kevorkian Robert C Use of ACE inhibitors for treatment of patients suffering from behavioral disorders
AU2001296493B2 (en) * 2000-10-03 2006-04-13 The Regents Of The University Of California Use of neuropeptide-Y antagonists in treatment of alcoholism
US8564661B2 (en) 2000-10-24 2013-10-22 Objectvideo, Inc. Video analytic rule detection system and method
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
US20050226918A1 (en) * 2001-08-13 2005-10-13 Macdonald Stuart G Delivery system for insulin and other therapeutic agents
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
ES2193875B2 (es) 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
SI1599468T1 (sl) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
UA92450C2 (ru) * 2003-01-14 2010-11-10 Арена Фармасьютикалз, Инк. 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
DE602004017703D1 (de) * 2003-02-24 2008-12-24 Arena Pharm Inc Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
JP2006519251A (ja) * 2003-03-04 2006-08-24 アデックス ファーマシューティカルズ ソシエテ アノニム ｍＧｌｕＲ５アンタゴニストとしての新規アミノピリジン誘導体
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
US7616233B2 (en) * 2003-06-26 2009-11-10 Fotonation Vision Limited Perfecting of digital image capture parameters within acquisition devices using face detection
ATE365167T1 (de) * 2003-07-10 2007-07-15 Neurogen Corp Aryl-substituierte benzo(d)isothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2222833B1 (es) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
UA91508C2 (ru) * 2004-06-02 2010-08-10 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
EA011671B1 (ru) * 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
DE602005024274D1 (de) * 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP5463034B2 (ja) * 2005-05-20 2014-04-09 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
BRPI0616245A2 (pt) * 2005-09-16 2011-06-14 Arena Pharm Inc modulador de metabolismo, seus usos, composiÇço farmaceutica compreendendo o mesmo, bem como mÉtodo para produÇço da referida composiÇço
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
AR057525A1 (es) * 2005-10-03 2007-12-05 Astrazeneca Ab Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
EP1961745A1 (en) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
JP5140080B2 (ja) 2006-09-21 2013-02-06 ラクオリア創薬株式会社 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
PE20081679A1 (es) * 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
CA2671845C (en) * 2006-12-07 2015-03-24 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008082839A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
AR070454A1 (es) * 2008-02-27 2010-04-07 Nycomed Gmbh Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
US8163763B2 (en) * 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
MX2011012520A (es) 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
SG182247A1 (en) * 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
AR077898A1 (es) * 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
WO2011058027A2 (en) * 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
ES2567168T3 (es) * 2009-11-12 2016-04-20 F. Hoffmann-La Roche Ag Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
KR20130058672A (ko) 2010-04-16 2013-06-04 제넨테크, 인크. ＰＩ3Ｋ/ＡＫＴ 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 ＦＯＸＯ３ａ
SG187956A1 (en) 2010-08-27 2013-03-28 Merck Patent Gmbh Furopyridine derivatives
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140004209A1 (en) 2010-12-22 2014-01-02 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
ES2691745T3 (es) 2011-04-08 2018-11-28 Janssen Sciences Ireland Uc Derivados de pirimidina para el tratamiento de infecciones víricas
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
DK2776439T3 (da) 2011-11-09 2018-10-22 Janssen Sciences Ireland Uc Purinderivater til behandling af virusinfektioner
IN2014CN04558A (da) 2011-11-23 2015-09-18 Cancer Rec Tech Ltd
CN104093722B (zh) * 2012-02-09 2016-07-27 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
ES2606638T3 (es) * 2012-02-21 2017-03-24 Merck Patent Gmbh Derivados de furopiridina
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
DK2872515T3 (da) 2012-07-13 2016-09-19 Janssen Sciences Ireland Uc Makrocykliske puriner til behandling af virusinfektioner
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
MX386924B (es) 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
US9663474B2 (en) 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
JP6216387B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
WO2014100071A2 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted pyrrolopyrimidines as hdm2 inhibitors
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
RU2015140573A (ru) 2013-02-25 2017-03-30 Дженентек, Инк. Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
WO2014154859A1 (en) 2013-03-29 2014-10-02 Janssen R&D Ireland Macrocyclic deaza-purinones for the treatment of viral infections
UA117586C2 (uk) 2013-05-24 2018-08-27 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні піридину для лікування вірусних інфекцій та інших захворювань
MX392130B (es) 2013-06-27 2025-03-21 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
ES2836881T3 (es) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales
US9371321B2 (en) 2014-01-09 2016-06-21 Astrazeneca Ab Azaindole derivatives
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
CZ305472B6 (cs) * 2014-04-30 2015-10-14 Masarykova Univerzita Substituované furo[3,2-b]pyridiny pro použití jako léčiva
GB201411236D0 (en) * 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
CN107454899B (zh) 2014-10-27 2020-05-29 大学健康网络 Ripk2抑制剂及用其治疗癌症的方法
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
TWI682899B (zh) 2015-03-15 2020-01-21 美商沙琛公司 用於改良沸石合成的結構定向劑
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
SG10202010317VA (en) 2016-09-29 2020-11-27 Janssen Sciences Ireland Unlimited Co Pyrimidine prodrugs for the treatment of viral infections and further diseases
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
EA202091530A1 (ru) * 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020118183A1 (en) * 2018-12-06 2020-06-11 Kapoor Tarun M 2,4-diaminopyrimidine bicycles for treating cancer
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
WO2021115286A1 (zh) * 2019-12-10 2021-06-17 成都倍特药业股份有限公司 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
TW202214106A (zh) * 2020-08-14 2022-04-16 瑞士商先正達農作物保護公司 化學方法
WO2024017227A1 (zh) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用
WO2026067383A1 (zh) * 2024-09-27 2026-04-02 上海轻胜谦远生物科技有限公司 咪唑并吡啶衍生物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA907618A (en) 1972-08-15 Woitun Eberhard 2-aminoalkylamino-thieno(3,2-d)pyrimidines and process for their production
US3883651A (en) 1969-08-08 1975-05-13 Boehringer Sohn Ingelheim Pharmaceutical compositions containing a 2-(aminoalkylamino)-4-amino-thieno{8 3,2-d{9 pyrimidine and method of use
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4731368A (en) 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation
US4808595A (en) 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
JPH0527391A (ja) 1991-07-23 1993-02-05 Konica Corp 新規な写真用カプラー
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
BR9307646A (pt) 1992-12-17 1999-05-25 Pfizer Pirrolopirimidinas como antagonistas de crf
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
US5461065A (en) 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5439923A (en) 1993-12-21 1995-08-08 Eli Lilly And Company Method of inhibiting seborrhea and acne
ES2109796T3 (es) 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
ES2135062T3 (es) 1994-06-16 1999-10-16 Pfizer Pirazolo y pirrolopiridinas.
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
WO1996012489A1 (en) 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
WO1996014307A1 (en) 1994-11-07 1996-05-17 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
JPH10506126A (ja) 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1997020821A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl derivatives
DK0778277T3 (da) 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
WO1997025041A1 (en) 1996-01-09 1997-07-17 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
JP2000504678A (ja) 1996-02-07 2000-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チオフェノピリミジン類
US5688796A (en) 1996-03-12 1997-11-18 Eli Lilly And Company Heterocyclic substituted benzothiophenes, compositions, and methods
DE69724941T2 (de) 1996-03-21 2004-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyridin-derivate
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
DK0920429T3 (da) 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
PT938486E (pt) 1996-08-23 2008-03-27 Novartis Ag Pirrolopirimidinas substituídas e processos para a sua preparação
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
AU6267198A (en) 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
WO1999007703A1 (en) 1997-08-05 1999-02-18 Pfizer Products Inc. 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
US6187777B1 (en) 2001-02-13
US6583154B1 (en) 2003-06-24
EP1054887B1 (en) 2006-04-12
DE69930835T2 (de) 2006-10-19
EP1054887A1 (en) 2000-11-29
ATE323088T1 (de) 2006-04-15
CY1105476T1 (el) 2010-07-28
AU2659099A (en) 1999-08-23
PT1054887E (pt) 2006-06-30
JP2003502272A (ja) 2003-01-21
AU747920B2 (en) 2002-05-30
SI1054887T1 (sl) 2006-08-31
CA2319275A1 (en) 1999-08-12
CA2319275C (en) 2007-10-16
WO1999040091A1 (en) 1999-08-12
ES2257851T3 (es) 2006-08-01
DE69930835D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
DE69930835D1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
SE9702773D0 (sv) Novel compounds
NO20022655D0 (no) <Beta>-2-adrenerge reseptoragonister
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
DE69821132D1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DE60032249D1 (de) AMINO-SUBSTITUIERTE PYRAZOLOi1,5-Aö-1,5-PYRIMIDINE UND PYRAZOLOi1,5-Aö-1,3,5-TRIAZINE
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
TR200103696T2 (tr) Makrofaj temizleyici reseptör antagonistleri.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
TR199901380A2 (xx) Di-ya da triazo-spiro$4,5] dekan t�revleri
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
BG106078A (en) Thio-oxindole derivatives
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya